The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 07, 2017

Filed:

Mar. 22, 2012
Applicants:

Cornelis Johannes Leenhouts, Groningen, NL;

Bert Jan Haijema, Groningen, NL;

Maarten Leonardus Van Roosmalen, Groningen, NL;

Petrus Josephus Marie Rottier, Groningen, NL;

Cornelis Alexander Maria DE Haan, Groningen, NL;

Berend Jan Bosch, Groningen, NL;

Inventors:

Cornelis Johannes Leenhouts, Groningen, NL;

Bert Jan Haijema, Groningen, NL;

Maarten Leonardus van Roosmalen, Groningen, NL;

Petrus Josephus Marie Rottier, Groningen, NL;

Cornelis Alexander Maria de Haan, Groningen, NL;

Berend Jan Bosch, Groningen, NL;

Assignee:

MUCOSIS B.V., Groningen, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/385 (2006.01); A61K 39/145 (2006.01); A61K 39/155 (2006.01); C07K 14/005 (2006.01); A61K 47/48 (2006.01); C12N 9/36 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/385 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/155 (2013.01); A61K 47/4833 (2013.01); A61K 47/48246 (2013.01); C07K 14/005 (2013.01); C12N 9/2462 (2013.01); C12Y 302/01017 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/6068 (2013.01); C07K 2319/20 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/70 (2013.01); C07K 2319/73 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01);
Abstract

The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. Also provided is a recombinant polypeptide comprising (A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumor origin, or antigenic part thereof, the antigenic domain being fused to (B) an oligomerization domain (OMD), said oligomerization domain being fused via (C) a linker domain to (D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium.


Find Patent Forward Citations

Loading…